Three-year Effectiveness and Safety of Vedolizumab Therapy for Inflammatory Bowel Disease

A Prospective Multi-centre Cohort Study

Aurelien Amiot; Melanie Serrero; Laurent Peyrin-Biroulet; Jerome Filippi; Benjamin Pariente; Xavier Roblin; Anthony Buisson; Carmen Stefanescu; Caroline Trang-Poisson; Romain Altwegg; Philippe Marteau; Thibaud Vaysse; Anne Bourrier; Stephane Nancey; David Laharie; Matthieu Allez; Guillaume Savoye; Jacques Moreau; Lucine Vuitton; Stephanie Viennot; Guillaume Bouguen; Vered Abitbol; Mathurin Fumery; Charlotte Gagniere; Yoram Bouhnik; on the behalf of the OBSERV-IBD study group, the GETAID


Aliment Pharmacol Ther. 2019;50(1):40-53. 

In This Article


Among patients with an inadequate response to anti-TNF agents, vedolizumab is effective for maintaining steroid-free clinical remission through week 162 in up to one-third of patients with UC and almost 20% of patients with CD. Vedolizumab therapy between week 54 and week 162 was characterised by stability of the clinical response, a good safety profile, and low loss of response in patients with UC, which was not observed in patients with CD. The predictors of vedolizumab persistence were related to severity of the disease in patients with UC and to age and disease phenotype in patients with CD. Further studies are warranted to determine whether those parameters should be taken into account before starting vedolizumab therapy.